Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Anti-PD-1/PD-L1

Intravenous injection at indicated dose for at least 6 months

DRUG

S-Adenosyl-Methionine

Taken orally at indicated dose for at least 6 months

Trial Locations (1)

RECRUITING

Zhongshan Hospital Fudan university, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER